12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zytiga abiraterone acetate regulatory update

Health Canada approved an NDS from Johnson & Johnson for Zytiga abiraterone acetate in combination with prednisone to treat metastatic, castration-resistant prostate cancer (CRPC) in patients who received prior docetaxel chemotherapy. J&J...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >